Palavras-chave
Insuficiência Hepática Aguda
Hospitalização
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Descrever o perfil clínico-epidemiológico de pacientes cirróticos com internações não eletivas na Fundação Santa Casa de Misericórdia do Pará. Métodos: Realizou-se um estudo do tipo observacional, descritivo e com delineamento transversal, a partir de análise de prontuários hospitalares eletrônicos de pacientes internados no período de abril de 2024 a setembro de 2024 em um Hospital de Referência. Resultados: Internações de 54 pacientes foram analisados, das quais a maioria apresentava diagnóstico prévio de cirrose hepática (N=38/54, 70%). A principal causa de cirrose hepática foi a alcoólica (48%), seguida pela doença hepática gordurosa não alcoólica (22%) e pela infecção crônica pelo Vírus da Hepatite C (17%). Insuficiência IHAC foi diagnosticada em 20% dos pacientes (N=11/54), com taxa de mortalidade significativamente maior quando comparados ao grupo de pacientes sem este diagnóstico (73% vs. 5%, p<0,001). Pacientes com IHAC também apresentaram maior necessidade de UTI, uso de hemocomponentes e intubação orotraqueal. Ademais, o estudo também mostrou que o escore MELD-NA não diferiu entre os pacientes que evoluíram a óbito e os que receberam alta hospitalar. Conclusão: Em conclusão, o presente estudo reafirma a gravidade da patologia e reforça a validade do uso de escores prognósticos, especialmente o CLIF-ACLF, neste perfil de pacientes.
Referências
AITHAL GP, et al. Guidelines on the management of ascites in cirrhosis. Gut, 2020;70(1):9–29.
ALLEN AM, et al. Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. Hepatology, 2016;64(6):2165–72.
BALCAR L, et al. Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute‐on‐chronic liver failure,2021;9(4):427–37.
CLÀRIA J, et al. The Acute-on-Chronic Liver Failure Syndrome, or When the Innate Immune System Goes Astray. The Journal of Immunology, 2016;197(10):3755–61.
CRONST J, et al. Acute-on-Chronic Liver Failure: DiagnósticoaoTransplanteHepático. Brazilian Journal of Transplantation, 2022;25(03):e042.
ENGELMANN C, et al. Validation of CLIF-C ACLF score to define a threshold for futility of intensive care support for patients with acute-on-chronic liver failure. Critical Care, 2018;22(1):254.
FERNANDES FC, et al.Acute-on-chronic liver failure: a retrospective review of cases at a transplantation center in Brazil. Acta Cirúrgica Brasileira, 2024; 39: e392624.
FERNÁNDEZ J, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut, 2017;67(10):1870–80.
FRANCHIS R, et al. Corrigendum to “Baveno VII – Renewing consensus in portal hypertension”. Journal of Hepatol, 2022;77(1):271–1.
FRIEDMAN SL. Liver fibrosis – from bench to bedside. Journal of Hepatology, 2003; 38 Suppl 1:S38–S53.
FURUICHI Y, NISHIGUCHI R, SATO K. Scoring system for prediction of mortality after endoscopic ligation in esophageal variceal bleeding. Digestive Endoscopy, 2024;36(10):1115-1117.
GUNARATHNE LS, et al. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics. World Journal of Gastroenterology, 2020;26(40):6111–40.
HSU C, et al. P59 Outcomes of patients with cirrhosis admitted to intensive care: a real-world district general hospital experience. Gut, 2024;73:A48.
JALAN R, et al. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. Journal of Hepatology, 2015;62(4):831–40.
KAMM DR, MCCOMMIS KS. Hepatic stellate cells in physiology and pathology. The Journal of Physiology, 2022;600(8):1825–37.
KUMAR R, et al. Acute-on-chronic liver failure. Clinical Medicine, 2020;20(5):501–4.
MAK LY, et al. Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions. Nature Reviews Gastroenterology & Hepatology. 2024; 21(12): 834–851.
MANSOUR D, MCPHERSON S. Management of decompensated cirrhosis. Clinical Medicine, 2018;18(Suppl 2):s60–5.
MATTOS ÂZ, MATTOS AA. Acute-on-chronic liver failure—old concepts made clearer. Translational Gastroenterology and Hepatology,2017;2(12):111–1.
MORAN-SALVADOR E, MANN J. Epigenetics and Liver Fibrosis. Cellular and Molecular Gastroenterology and Hepatology, 2017;4(1):125–34.
MOREAU R, et al. Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. Gastroenterology, 2013;144(7):1426-1437.e9.
NADIM MK, et al. Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. Journal of Hepatology, 2016;64(3):717–35.
PICON RV, et al. Chronic liver failure-consortium acute-on-chronic liver failure and acute decompensation scores predict mortality in Brazilian cirrhotic patients. World Journal of Gastroenterology, 2017;23(28):5237-5245.
PUTIGNANO A, GUSTOT T. New concepts in acute-on-chronic liver failure: Implications for liver transplantation. Liver Transplantation, 2017;23(2):234–43.
RINELLA ME, et al. AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease. Hepatology, 2023;77(5):1797–1835.
SALIBA F, et al. Cirrhotic patients in the ICU. Current Opinion in Critical Care. 2013;19(2):154–60.
SERPER M, et al. Patterns of Care Utilization and Hepatocellular Carcinoma Surveillance: Tracking Care Across the Pandemic. The American journal of gastroenterology, 2023;118(2):294–303
SILVA PES, et al.Single-centre validation of the EASL-CLIF Consortium definition of acute-on-chronic liver failure and CLIF-SOFA for prediction of mortality in cirrhosis. Liver International, 2014;35(5):1516–23.
SINGAL AK, et al. ACG Clinical Guideline: Alcoholic Liver Disease. The American Journal of Gastroenterology, 2018;113(2):175–94.
SINGH JA, et al. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med, 2016;14(1):137.
TREBICKA J, et al. Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers. Gut, 2024;73(6):1015-1024.
WEIL D, et al.Prognosis of cirrhotic patients admitted to intensive care unit: a meta-analysis. Ann Intensive Care, 2017;7(1):33.
WONG RJ, et al. Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States. Gastroenterology, 2015;148(3):547–55.